IHVR-19029 is a potent endoplasmic reticulum (ER) α-glucosidases I and II inhibitor, with an IC 50 of 0.48 μM for ER a-glucosidase I. IHVR-19029 efficiently blocks the replication of several hemorrhagic fever viruses, such as Dengue virus (DENV), Ebola virus (EBOV) and Rift Valley fever virus. The combination of IHVR-19029 with Favipiravir improves the antiviral efficacy. In Vitro IHVR-19029 efficiently inhibits Bovine viral diarrhea virus (BVDV), Tacaribe virus (TCRV) and Dengue virus (DENV) with EC 50 s of 0.25, 0.74, and 1.25 μM, respectively.\nThe combination of IHVR-19029 and Favipiravir synergistically inhibits the replication of Yellow fever and Ebola viruses in cultured cells . MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo IHVR-19029 (25-75 mg/kg; I.p.; twice daily for 10 days) inhibits EBOV and MARV infection in mice. IHVR-19029 (5 mg/kg; i.v.) has AUC, C 0 , T 1/2 , CL and V d values of 1383 μg*h/mL, 1.79 μg/mL, 1.2 hours, 3.49 L/h/kg, and 3.0 L/kg, respectively. IHVR-19029 (75/5/5 mg/kg; p.o./i.m./i.p.) has AUC values of 945/1839/983 μg*h/mL, C max values of 0.26/1.23/1.33 μg/ml, T max values of 2.1/0.1/0.17 hours, and F values of 4.6/71/133%, respectively. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: BALB/c mice (12 week 233 of age) (MARV infection)Dosage: 25, 75 mg/kg Administration: I.p.; twice daily, until 10 days Result: Significant protection of Marburg virus (MARV) induced death were observed. Animal Model: C57B1/6 mice (8–12 week of age) (EBOV infection)Dosage: 25, 75 mg/kg Administration: I.p.; twice daily for 10 days Result: Significant survival were observed. Form:Solid